Our data underscore the notion that GPx2 loss drives tumor heterogeneity, resulting in a metabolically hybrid tumor cell population, which in turn activates both AMPK and HIF1α (GLUT1) signaling, likely due to ROS signaling (17, 53). The gene discussed is GPX2; the disease is neoplasm.